GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459–80.
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
Abu Bakar N, Tanprawate S, Lambru G, Torkamani M, Jahanshahi M, Matharu M (2016) Quality of life in primary headache disorders: A review. Cephalalgia 36(1):67–91
Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137.
Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A et al (2007) The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27(3):193–210
Katsarava Z, Buse DC, Manack AN, Lipton RB (2012) Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep 16(1):86–92
Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain 23(1):67
Article PubMed PubMed Central Google Scholar
Meng J, Ovsepian SV, Wang J, Pickering M, Sasse A, Aoki KR et al (2009) Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci 29(15):4981–4992
Article CAS PubMed PubMed Central Google Scholar
Vecchia D, Pietrobon D (2012) Migraine: a disorder of brain excitatory-inhibitory balance? Trends Neurosci 35(8):507–520
Article CAS PubMed Google Scholar
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF et al (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68(5):343–349
Article CAS PubMed Google Scholar
Silberstein S, Lipton R, Dodick D, Freitag F, Mathew N, Brandes J et al (2009) Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 49(8):1153–1162
Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E et al (2012) Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78(17):1337–1345
Article CAS PubMed PubMed Central Google Scholar
Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50(6):921–936
Inan LE, Inan N, Unal-Artık HA, Atac C, Babaoglu G (2019) Greater occipital nerve block in migraine prophylaxis: Narrative review. Cephalalgia 39(7):908–920
Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425–434
Article CAS PubMed Google Scholar
Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R et al (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: A multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14(11):1081–1090
Article CAS PubMed Google Scholar
Dodick DW, Goadsby PJ, Spierings ELH, Scherer JC, Sweeney SP, Grayzel DS (2014) Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 13(9):885–892
Article CAS PubMed Google Scholar
Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J et al (2019) Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia 39(9):1075–1085
Dhillon S (2020) Eptinezumab: First Approval. Drugs 80(7):733–739
Article CAS PubMed Google Scholar
Ailani J, Lipton RB, Hutchinson S, Knievel K, Lu K, Butler M et al (2020) Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial. Headache 60(1):141–152
Article PubMed PubMed Central Google Scholar
Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM et al (2021) Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet 397(10268):51–60
Article CAS PubMed Google Scholar
Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L et al (2021) Atogepant for the Preventive Treatment of Migraine. N Engl J Med 385(8):695–706
Article CAS PubMed Google Scholar
Martelletti P, Edvinsson L, Ashina M (2019) Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs). J Headache Pain 20(1):60
Article PubMed PubMed Central Google Scholar
Wang SJ, Chen PK, Fuh JL (2010) Comorbidities of migraine Front Neurol 1:16
Richards D (2011) Prevalence and clinical course of depression: a review. Clin Psychol Rev 31(7):1117–1125
Jacoby A, Baker GA, Steen N, Potts P, Chadwick DW. The clinical course of epilepsy and its psychosocial correlates: findings from a U.K. Community study. Epilepsia. 1996;37(2):148–61.
Kendrick T, Geraghty AWA., Bowers H, Stuart B, Leydon G, May C. REDUCE (Reviewing long-term antidepressant use by careful monitoring in everyday practice) internet and telephone support to people coming off long-term antidepressants: protocol for a randomised controlled trial. Trials. 2020;21(1):419.
Schweitzer I, Maguire K (2001) Stopping antidepressants. Aust Prescr 24(1):13–15
Eveleigh R, Speckens A, van Weel C, Oude Voshaar R, Lucassen P (2019) Patients’ attitudes to discontinuing not-indicated long-term antidepressant use: barriers and facilitators. Ther Adv Psychopharmacol 9:2045125319872344
Article PubMed PubMed Central Google Scholar
Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G et al (2008) Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 22(4):343–396
Article CAS PubMed Google Scholar
Bair MJ, Robinson RL, Eckert GJ, Stang PE, Croghan TW, Kroenke K (2004) Impact of pain on depression treatment response in primary care. Psychosom Med 66(1):17–22
Halperin D, Reber G (2007) Influence of antidepressants on hemostasis. Dialogues Clin Neurosci 9(1):47–59
Article PubMed PubMed Central Google Scholar
Shelton RC (2001) Steps Following Attainment of Remission: Discontinuation of Antidepressant Therapy. Prim Care Companion J Clin Psychiatry 3(4):168–174
Article PubMed PubMed Central Google Scholar
Van Leeuwen E, van Driel ML, Horowitz MA, Kendrick T, Donald M, De Sutter AIM, et al. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. Cochrane Database of Systematic Reviews. 2021;4(4):CD013495.
Bschor T, Bonnet U, Pitzer M, Baethge C, Lieb K, Gertz HJ et al (2022) Stopping antidepressants: withdrawal symptoms and rebound effects: Review and practical recommendations. Nervenarzt 93(1):93–101
Article CAS PubMed Google Scholar
Kanner AMBMM (2022) Antiseizure Medications for Adults With Epilepsy: A Review. JAMA 327(13):1269–1281
Article CAS PubMed Google Scholar
Ayuga Loro F, Gisbert Tijeras E, Brigo F. Rapid versus slow withdrawal of antiepileptic drugs. Cochrane Database Syst Rev. 2020;1(1):CD005003.
Beghi E, Giussani G, Grosso S, Iudice A, La Neve A, Pisani F et al (2013) Withdrawal of antiepileptic drugs: guidelines of the Italian League Against Epilepsy. Epilepsia 54(Suppl 7):2–12
Article CAS PubMed Google Scholar
Gloss D, Pargeon K, Pack A, Varma J, French JA, Tolchin B et al (2021) Antiseizure Medication Withdrawal in Seizure-Free Patients: Practice Advisory Update Summary: Report of the AAN Guideline Subcommittee. Neurology 97(23):1072–1081
Strozzi I, Nolan SJ, Sperling MR, Wingerchuk DM, Sirven J. Early versus late antiepileptic drug withdrawal for people with epilepsy in remission. Cochrane Database Syst Rev. 2015;2015(2):CD001902.
Lossius MI, Hessen E, Mowinckel P, Stavem K, Erikssen J, Gulbrandsen P et al (2008) Consequences of antiepileptic drug withdrawal: a randomized, double-blind study (Akershus Study). Epilepsia 49(3):455–463
Chadwick D, Taylor J, Johnson T. Outcomes after seizure recurrence in people with well-controlled epilepsy and the factors that influence it. The MRC Antiepileptic Drug Withdrawal Group. Epilepsia. 1996;37(11):1043–50.
Medical Research Council Antiepileptic Drug Withdrawal Study Group, P. Bessant, D. Chadwick, B. Eaton, J. Taylor, A. Holland, et al. Randomised study of antiepileptic drug withdrawal in patients in remission. The Lancet. 1991;337(8751):1175–80.
Terman SW, Wang C, Wang L, Braun KPJ, Otte WM, Slinger G et al (2022) Reappraisal of the Medical Research Council Antiepileptic Drug Withdrawal Study: Contamination-adjusted and dose-response re-analysis. Epilepsia 63(7):1724–1735
Article CAS PubMed PubMed Central Google Scholar
Wang X, He R, Zheng R, Ding S, Wang Y, Li X et al (2019) Relative Seizure Relapse Risks Associated with Antiepileptic Drug Withdrawal After Different Seizure-Free Periods in Adults with Focal Epilepsy: A Prospective. Controlled Follow-Up Study CNS Drugs 33(11):1121–1132
留言 (0)